(SCL) Stepan - Ratings and Ratios
Surfactants, Polymers, Commodity Chemicals
SCL EPS (Earnings per Share)
SCL Revenue
Description: SCL Stepan
Stepan Company (NYSE:SCL) is a US-based specialty chemicals company. Its business is subject to various economic drivers, including fluctuations in raw material costs, demand from downstream industries such as consumer goods and pharmaceuticals, and global supply chain dynamics.
The companys financial performance is reflected in its income statement, where income tax expense is a significant item. Analyzing this expense can provide insights into Stepans tax strategy and its impact on profitability. Key performance indicators (KPIs) such as the effective tax rate and tax-adjusted margins can be useful in evaluating the companys financial health.
Stepans market capitalization is approximately $1.1 billion, with a price-to-earnings ratio of 19.26, indicating a moderate valuation relative to its earnings. The forward P/E ratio is lower, suggesting potential earnings growth. Return on Equity (RoE) is around 4.80%, which may be considered relatively low, potentially indicating inefficiencies in capital allocation or profitability issues.
To further analyze Stepans prospects, it is essential to examine its business segments, product portfolio, and geographic diversification. The specialty chemicals industry is highly competitive, and companies must differentiate themselves through innovation, quality, and customer service. Stepans ability to manage its raw material costs, invest in research and development, and expand its customer base will be crucial in driving future growth.
From a trading perspective, Stepans stock price has been trending downward, with its current price below its 20-day, 50-day, and 200-day moving averages. The Average True Range (ATR) indicates moderate volatility, and the beta suggests that the stock is slightly less volatile than the overall market. These technical indicators can be used to inform trading decisions, such as identifying potential entry and exit points.
SCL Stock Overview
| Market Cap in USD | 1,143m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception | 1992-03-17 |
SCL Stock Ratings
| Growth Rating | -75.8% |
| Fundamental | 41.5% |
| Dividend Rating | 61.4% |
| Return 12m vs S&P 500 | -43.8% |
| Analyst Rating | 3.50 of 5 |
SCL Dividends
| Dividend Yield 12m | 2.81% |
| Yield on Cost 5y | 1.44% |
| Annual Growth 5y | 5.97% |
| Payout Consistency | 100.0% |
| Payout Ratio | 61.4% |
SCL Growth Ratios
| Growth Correlation 3m | -52.4% |
| Growth Correlation 12m | -86.1% |
| Growth Correlation 5y | -92.9% |
| CAGR 5y | -14.04% |
| CAGR/Max DD 5y | -0.22 |
| Sharpe Ratio 12m | -0.90 |
| Alpha | -52.68 |
| Beta | 1.189 |
| Volatility | 33.35% |
| Current Volume | 148.3k |
| Average Volume 20d | 125k |
| Stop Loss | 48.1 (-3.9%) |
| Signal | 0.00 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (58.0m TTM) > 0 and > 6% of Revenue (6% = 135.6m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 0.96pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.68% (prev 9.62%; Δ 1.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 109.1m > Net Income 58.0m (YES >=105%, WARN >=100%) |
| Net Debt (383.2m) to EBITDA (193.8m) ratio: 1.98 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (22.9m) change vs 12m ago -0.22% (target <= -2.0% for YES) |
| Gross Margin 12.38% (prev 12.60%; Δ -0.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 94.88% (prev 93.77%; Δ 1.11pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.31 (EBITDA TTM 193.8m / Interest Expense TTM 18.1m) >= 6 (WARN >= 3) |
Altman Z'' 3.66
| (A) 0.10 = (Total Current Assets 914.8m - Total Current Liabilities 673.3m) / Total Assets 2.42b |
| (B) 0.53 = Retained Earnings (Balance) 1.29b / Total Assets 2.42b |
| (C) 0.03 = EBIT TTM 77.9m / Avg Total Assets 2.38b |
| (D) 1.00 = Book Value of Equity 1.17b / Total Liabilities 1.17b |
| Total Rating: 3.66 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 41.49
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 4.35% = 2.17 |
| 3. FCF Margin 3.29% = 0.82 |
| 4. Debt/Equity 0.53 = 2.36 |
| 5. Debt/Ebitda 3.40 = -2.22 |
| 6. ROIC - WACC -3.38% = -4.22 |
| 7. RoE 4.80% = 0.40 |
| 8. Rev. Trend -60.37% = -3.02 |
| 9. Rev. CAGR -6.68% = -1.11 |
| 10. EPS Trend -27.70% = -0.69 |
| 11. EPS CAGR -36.26% = -2.50 |
What is the price of SCL shares?
Over the past week, the price has changed by -2.84%, over one month by -8.73%, over three months by -8.54% and over the past year by -34.27%.
Is Stepan a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SCL is around 39.75 USD . This means that SCL is currently overvalued and has a potential downside of -20.55%.
Is SCL a buy, sell or hold?
- Strong Buy: 0
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SCL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 85 | 69.9% |
| Analysts Target Price | 85 | 69.9% |
| ValueRay Target Price | 43.7 | -12.7% |
Last update: 2025-08-27 04:47
SCL Fundamental Data Overview
CCE Cash And Equivalents = 88.9m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 19.9016
P/E Forward = 20.0401
P/S = 0.5058
P/B = 0.9451
P/EG = 4.34
Beta = 0.97
Revenue TTM = 2.26b USD
EBIT TTM = 77.9m USD
EBITDA TTM = 193.8m USD
Long Term Debt = 383.2m USD (from longTermDebt, last quarter)
Short Term Debt = 274.8m USD (from shortLongTermDebt, last quarter)
Debt = 658.0m USD (Calculated: Short Term 274.8m + Long Term 383.2m)
Net Debt = 383.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.71b USD (1.14b + Debt 658.0m - CCE 88.9m)
Interest Coverage Ratio = 4.31 (Ebit TTM 77.9m / Interest Expense TTM 18.1m)
FCF Yield = 4.35% (FCF TTM 74.4m / Enterprise Value 1.71b)
FCF Margin = 3.29% (FCF TTM 74.4m / Revenue TTM 2.26b)
Net Margin = 2.57% (Net Income TTM 58.0m / Revenue TTM 2.26b)
Gross Margin = 12.38% ((Revenue TTM 2.26b - Cost of Revenue TTM 1.98b) / Revenue TTM)
Tobins Q-Ratio = 1.46 (Enterprise Value 1.71b / Book Value Of Equity 1.17b)
Interest Expense / Debt = 0.83% (Interest Expense 5.49m / Debt 658.0m)
Taxrate = 16.66% (from yearly Income Tax Expense: 10.1m / 60.4m)
NOPAT = 64.9m (EBIT 77.9m * (1 - 16.66%))
Current Ratio = 1.36 (Total Current Assets 914.8m / Total Current Liabilities 673.3m)
Debt / Equity = 0.53 (Debt 658.0m / last Quarter total Stockholder Equity 1.24b)
Debt / EBITDA = 3.40 (Net Debt 383.2m / EBITDA 193.8m)
Debt / FCF = 8.84 (Debt 658.0m / FCF TTM 74.4m)
Total Stockholder Equity = 1.21b (last 4 quarters mean)
RoA = 2.40% (Net Income 58.0m, Total Assets 2.42b )
RoE = 4.80% (Net Income TTM 58.0m / Total Stockholder Equity 1.21b)
RoCE = 4.90% (Ebit 77.9m / (Equity 1.21b + L.T.Debt 383.2m))
RoIC = 3.48% (NOPAT 64.9m / Invested Capital 1.87b)
WACC = 6.85% (E(1.14b)/V(1.80b) * Re(10.40%)) + (D(658.0m)/V(1.80b) * Rd(0.83%) * (1-Tc(0.17)))
Shares Correlation 5-Years: -70.0 | Cagr: -0.40%
Discount Rate = 10.40% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 68.04% ; FCFE base≈64.6m ; Y1≈58.0m ; Y5≈49.6m
Fair Price DCF = 27.35 (DCF Value 618.7m / Shares Outstanding 22.6m; 5y FCF grow -12.65% → 3.0% )
Revenue Correlation: -60.37 | Revenue CAGR: -6.68%
Rev Growth-of-Growth: 18.29
EPS Correlation: -27.70 | EPS CAGR: -36.26%
EPS Growth-of-Growth: 131.0
Additional Sources for SCL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle